GTR Home > Tests > Tempus xO assay

Overview

Test name

Help

Tempus xO assay (xO assay)

Purpose of the test

Help

This is a clinical test intended for Help: Therapeutic management

Condition

Help

1 condition tested. Click Indication tab for more information.

Methodology

Help
Molecular Genetics
RRNA analysis
Whole Transcriptome RNA sequencing
CSequence analysis of the entire coding region
Next-Generation (NGS)/Massively parallel sequencing (MPS)
  • Illumina HiSeq 4000 System

Summary of what is tested

1713 genes and variants, 1 analytes. Click Methodology tab for more information.

Genes

Analytes

  • whole RNA transcriptome

Clinical validity

Help

Not provided

Clinical utility

Help

Guidance for management

Citations
  • Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. - PubMed ID: 25567908
  • Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. - PubMed ID: 26304871
  • Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. - PubMed ID: 26378224
  • Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). - PubMed ID: 26777916
  • Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. - PubMed ID: 26952546
  • Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers. - PubMed ID: 27016222
  • Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. - PubMed ID: 27197177
  • Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. - PubMed ID: 27273579
  • Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. - PubMed ID: 27908594
  • Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. - PubMed ID: 28481359
  • Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations. - PubMed ID: 28497333
  • Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center. - PubMed ID: 28550027
  • Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials. - PubMed ID: 28701572
  • Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. - PubMed ID: 28723536
  • Integrative clinical genomics of metastatic cancer. - PubMed ID: 28783718
  • Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. - PubMed ID: 28825054
  • Targeting the Oncogenic Transcriptional Regulator MYB in Adenoid Cystic Carcinoma by Inhibition of IGF1R/AKT Signaling. - PubMed ID: 28954282
  • Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies. - PubMed ID: 28961851
  • Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib. - PubMed ID: 28979145
  • A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer. - PubMed ID: 29021377

Testing strategy

Help

The xO Assay is an NGS-based cancer genome profiling test that interrogates 1,711 cancer-related genes in tumor tissue with a matched normal sample, as well as tumor whole transcriptome RNA for gene rearrangement detection. The assay interrogates SNVs, CNVs, indels, rearrangements, and TMB and is intended for patients with solid cancers. The Tempus xO assay uses saliva and blood for germline DNA, and FFPE for tumor DNA and RNA. A patient can consent to or opt out of receiving genetic cancer predisposition results by completing the Patient Informed Consent form. The Tempus xO gene panel has been designed to specifically target genes known in the literature to be linked with response or resistance to targeted therapies, resistance to standard of care, or toxicities associated with treatment. Furthermore, the Tempus xO assay allows for clinical trial routing based on the most recent literature and clinical trial availability.

How to order

Help

To order the Tempus xO test: 1. Retrieve a Tempus blood or saliva collection kit. All required forms are contained in the box. 2. Complete the Consent Form with the patient. 3. Complete the Requisition Form. Physician and Patient signatures are both required. 4. Complete the Financial Assistance Form with the patient. 5. Fax the Requisition Form, Financial Assistance Form, and accompanying documents to Tempus at 708.575.1789. 6. Once Tempus receives the fax, Tempus will request the tumor specimen (FFPE ) from pathology. 7. Retrieve a normal sample of blood or saliva from the patient and ship it using the enclosed FedEx label. Include faxed documents in the package.
Order URL Help: https://www.tempus.com/providers.html

Test services

Help
  • Clinical Testing/Confirmation of Mutations Identified Previously
  • Next generation DNA sequencing of 1,711 genes
  • Whole Transcriptome RNA sequencing

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.

Support Center